[Brief Introduction of Seminar]

We will introduce LONG PEPPER EXTRACT POWDER M, an ingredient that can be used to make two health claims under the Japanese Foods with Function Claims (FFC) system: "reducing swelling" and "improving cold sensitivity". 

It has been confirmed that this ingredient reduces swelling by stably maintaining the structure of capillaries and lymphatic vessels. 

In Korea, it will be marketed as a general food ingredient, but since swelling was newly added to the health claims in Korea in 2024, We think it is a very interesting topic.

[Brief Introduction of Speaker]

Ms. Momoka Kajita from the International Sales Department of Maruzen Pharmaceuticals Co., Ltd. will be the speaker for this seminar.

With a history dating back to 1938, Maruzen Pharmaceuticals has continuously pursued the potential of natural plants by identifying effective extraction methods and developing safe, high-quality functional ingredients.​ 

[Brief Introduction of Seminar]

Bioavailability is one of the biggest hurdles in nutraceutical formulation, as many bioactives lose efficacy due to poor absorption. This session presents two technologies developed by K. Patel Phyto Extractions to solve this challenge, CurcuVail®, a bioavailability-enhanced curcumin built on proprietary non-liposomal technology, and VesiMatrix™, a liposomal delivery platform for a range of actives. Backed by clinical data and KP Phyto's vertically integrated manufacturing, attendees will learn how to evaluate which bioavailability solution best fits their formulation needs.

[Brief Introduction of Speaker]

Hana Oh is an R&D specialist at O&Company, a longstanding distributor partner of K. Patel Phyto Extractions in South Korea. With years of experience in nutraceutical research and formulation, she brings a practical, market-facing perspective on bioavailability technologies and their real-world application in product development.​ 

[Brief Introduction of Seminar]

The Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act) was amended in 2025. The amendments will be implemented in stages between 2026 and 2028. This seminar explains the points to consider when exporting APIs to Japan.

[Brief Introduction of Speaker]

The speaker has served as Chairperson of the JPTA—an association of API importers—since 2019 and is also active in ensuring the stable supply of imported APIs as a member of a committee organized by the MHLW.​ 

[Brief Introduction of Seminar]

This presentation highlights Japan’s Foods with Function Claims (FFC) system and its impact on market growth, innovation, and consumer trust.

[Brief Introduction of Speaker]

Hidekazu Kawakubo is Chairman of JAOHFA, leading industry collaboration and policy initiatives in Japan’s health food sector.​ 

[Brief Introduction of Seminar]

This presentation will provide an overview of the current landscape of bioequivalence (BE) studies in Indonesia, including the role of BE studies in supporting generic drug development and ensuring therapeutic equivalence in accordance with Indonesian regulatory requirements. The session will also discuss the practical implementation of BE studies by Contract Research Organizations (CROs), including clinical study conduct, bioanalytical processes, quality management systems, and the development of facilities and capabilities in Indonesia, such as clinical research sites, bioanalytical laboratories, and LC–MS/MS technologies to support end-to-end bioequivalence studies.

[Brief Introduction of Speaker]

Mr. Andi Darmawan serves as Head of Technical Operation at PT Biometrik Riset Indonesia, a Contract Research Organization (CRO) specializing in Bioavailability and Bioequivalence (BA/BE) studies. With more than 17 years of experience in the pharmaceutical and bioanalytical field, he has been actively involved in the technical and operational aspects of bioequivalence studies, including study strategy, bioanalytical processes, and collaboration with pharmaceutical companies. He regularly engages in scientific discussions to support effective study design, address technical challenges, and enhance the success of BE studies. His expertise combines scientific knowledge with practical industry experience, supporting partnerships with both local and international pharmaceutical companies.​ 

[Brief Introduction of Seminar]

“Optimizing Human Health: Enhanced Bioavailability Through Liposome and DFS Technology Platforms”

LipsoBio® is Botanic Healthcare's proprietary portfolio of advanced liposomal ingredients, developed to address one of the most significant challenges in nutritional supplementation—achieving consistent and efficient nutrient absorption. Spanning a diverse range of vitamins, minerals, nutraceuticals, botanicals, and synergistic blends, the LipsoBio® platform combines innovative delivery technology with scientific validation to offer next-generation ingredient solutions for the global nutraceutical market.

At the core of the LipsoBio® platform is DFS Technology™ (Dietary Fibre Stabilised), a proprietary encapsulation platform designed to enhance the stability, integrity, and performance of liposomal formulations. Beyond formulation development, LipsoBio® ingredients undergo comprehensive characterization through Transmission Electron Microscopy (TEM), particle size and zeta potential analysis, and Caco-2 permeability evaluation, ensuring consistent liposomal quality, stability, and absorption potential.

A key differentiator of the LipsoBio® portfolio is its strong commitment to clinical validation. The portfolio is anchored by six clinically validated branded ingredients—Lipomac® (Liposomal Vitamin C), Lipoglo® (Liposomal Glutathione), Ironnox® (Liposomal Iron), LipoLush® (Liposomal Collagen), LipoMg® (Liposomal Magnesium Bisglycinate), and LipoQ10® (Liposomal CoQ10)—each evaluated through controlled human clinical studies. These studies have demonstrated superior absorption, bioavailability, and functional efficacy compared with conventional formulations. Collectively, these clinically proven ingredients address key health and wellness areas including, enhanced skin health outcomes, improved iron status in individuals with iron deficiency anemia, better muscle health and sleep quality, and enhanced energy metabolism, reduced fatigue, and superior absorption.

By integrating DFS Technology™, analytical validation, and clinical substantiation, LipsoBio® provides brands and formulators with a portfolio of evidence-based ingredients that set a new benchmark for performance-driven liposomal nutrition

[Brief Introduction of Speaker]

Dr. Shiv holds a Master’s degree in Pharmacy from Rajiv Gandhi University of Health Sciences, Karnataka, and a Ph.D. in Pharmaceutical Sciences from Dr. H.S. Gour University, India. A recognized leader in the nutraceutical and herbal research space, he received the prestigious “Young Scientist” award for his contributions to pharma, biotech, and herbal drug research at the international level, honored by Johns Hopkins University (USA) and Colombo University (Sri Lanka).

He has authored over 50 research papers and presented at more than 75 international conferences. With 50+ published articles on nutraceuticals across global magazines and media platforms, Dr. Shiv is also the recipient of the Best Product Innovation Award from FKCCI for a patented turmeric formulation (US Patent Application 20160256513).

Having traveled to 25 countries, Dr. Shiv brings a global perspective through his active participation in international expos and industry events across the USA, Europe, and Asia.​ 

[Brief Introduction of Seminar]

1. Market trends in nutricosmetics: key hero ingredients and majorfunctional domains.

2. Three integrated solutions combining cosmetic ingredients withfunctional food raw materials for beauty-from-within.

3. Key oral nutraceutical actives powering these solutions - their scientific rationale and synergy with topical actives.

[Brief Introduction of Speaker]

Chelsea Zhang, graduated from the Department of Food and Nutrition at Korea University, currently serves as the Technical Marketing Manager at the Nutrition& Health Raw Materials of Bloomage Biotechnology. With years of experience in the health food sector, she is familiar with food-related laws and regulations as well as the market, particularly in various functional areas such as intrinsic beauty, improving sleep, and cognitive health. She has successfully provided comprehensive solutions for major domestic and international enterprises.​ 

[Brief Introduction of Seminar]

As the market shifts toward regenerative aesthetics, reconstructing the Extracellular Matrix (ECM) is the ultimate key. We will introduce new cutting-edge biomaterials，including dECM, PDRN/PN, recombinant collagen, chondroitin sulfate and carboxymethyl chitosan — that synergistically restore the cellular microenvironment. Backed by scientific evidence, these high-purity ingredients empower medical device manufacturers to formulate next-generation, high-performance injectables. Explore the B2B solutions that will redefine the future of youth.

[Brief Introduction of Speaker]

Bloomage Biotechnology, Pharmaceutical Materials BG-Aesthetic Materials Division

Sales Director

- KS Bio, Overseas Business Department Team Leader

- Guangzhou Sumira Academy Advisor

- Advisor at Shanghai Suenmi Plastic Surgery Hospital

- Haesung Korea Biotech, Sales Team Leader​ 

[Brief Introduction of Seminar]

An overview will be presented on the different requirements around the globe for the introduction of API related changes. The comparison will include the major markets around the world.

For some often-occurring API related changes, it will be shown what the regulatory requirements and timelines are. It will become clear that this is an issue that needs further global harmonization. 

[Brief Introduction of Speaker]

Marieke van Dalen studied chemical technology.

She leads her own consultancy in the Netherlands after 38 years of experience in the API industry, always in the regulatory field. Her latest position in industry was with Aspen API in the Netherlands.

She was a Board member of APIC (the European API organization) and represented APIC often in meetings with Health Authorities all around the world.

She chaired the Regulatory Affairs workgroup of APIC for some years and later on co-chaired the Japan and EDQM task forces.

Marieke is today also a trainer for the European Compliance Academy in a number of API regulatory oriented trainings.​